|Bid||0.00 x 900|
|Ask||0.00 x 1400|
|Day's Range||19.18 - 20.07|
|52 Week Range||9.01 - 29.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.50|
CANTON, Mass., July 10, 2018-- Collegium Pharmaceutical, Inc. today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, ...
Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.
While small-cap stocks, such as Collegium Pharmaceutical Inc (NASDAQ:COLL) with its market cap of US$879.63m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Outfront ...
Collegium Pharmaceutical, Inc. (COLL) today announced that Joseph Ciaffoni, Executive Vice President and Chief Operating Officer at Collegium will be promoted to Chief Executive Officer and join the board of directors effective July 1, 2018. Mr. Ciaffoni will succeed Michael T. Heffernan as Chief Executive Officer.
CANTON, Mass., May 30, 2018-- Collegium Pharmaceutical, Inc. today announced that management will present at the following investor conferences in June:. The Jefferies Global Healthcare Conference on Thursday, ...
LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.
Net revenue of $63.7 million, compared to $10.8 million in Q4 2017 Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization Conference ...
CANTON, Mass., May 02, 2018-- Collegium Pharmaceutical, Inc. today announced that management will present at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ...
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Collegium Pharmaceutical, Inc. (NASDAQ: COLL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.